Mantle Cell Lymphoma

AbbVie has announced the intention to voluntarily withdraw indications for ibrutinib in patients with mantle cell lymphoma who have previously received at least 1 therapy and in those with marginal zone lymphoma who require systemic treatment and have received at least 1 prior anti–CD20-based therapy.

Zachary Epstein-Peterson, MD, discusses available treatment approaches for patients with mantle cell lymphoma who are transplant eligible or ineligible.

Nirav N. Shah, MD, discusses the investigation of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens in patients with relapsed or refractory mantle cell lymphoma.

Venetoclax, alone or in combination with a BTK inhibitor, improved overall response rate in patients with pretreated, high-risk mantle cell lymphoma, according to findings from a retrospective study. However, the BCL-2 inhibitor was associated with short durations of progression-free survival.

Acalabrutinib has received conditional approval from the National Medical Products Administration in China for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.

A real-world analysis exploring the outcomes of inpatient vs outpatient administration of CAR T-cell therapy in patients with mantle cell lymphoma and follicular lymphoma demonstrated both similarities and some differences between the 2 patient populations.

Consolidative autologous stem cell transplant was associated with a statistically significant lower overall mortality risk and higher overall survival probability in patients with mantle cell lymphoma vs those who did not receive consolidation.

First-line consolidative autologous stem cell transplant following first complete remission, with or without maintenance rituximab, did not result in improved overall survival for patients with mantle cell lymphoma.

Akash Mukherjee, MD, discusses the use of post-transplant maintenance rituximab in patients with mantle cell lymphoma who have received autologous stem cell transplant and considerations for using bendamustine/rituximab or BR plus cytarabine in elderly patients who are unfit for transplant.

Zachary Epstein-Peterson, MD, discusses important updates in mantle cell lymphoma treatment, including the safety and feasibility of disease observation in patients with indolent MCL and the treatment of patients with TP53-mutated MCL.

Nirav N. Shah, MD, explains the choice to evaluate LV20.19 CAR in MCL, key efficacy and safety data from the follow-up study of this agent, and ongoing efforts to potentially expand its use across other B-cell malignancies.

Andre H. Goy, MD, discusses the appropriate monitoring and management of patients with mantle cell lymphoma who display genetic abnormalities but are not considered to be high risk.

Andre H. Goy, MD, discusses differentiating between disease presentations in mantle cell lymphoma.

Pallawi Torka, MD, discusses the BTK inhibitors available for treatment of patients with relapsed/refractory mantle cell lymphoma.

Farrukh Awan, MD, discusses the potential use of BTK inhibitors in the management of mantle cell leukemia.

Nirav N. Shah, MD, discusses the safety of the lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens, as well as future efforts from a phase 1/2 study of the product in patients with relapsed/refractory mantle cell lymphoma.

When treating patients with mantle cell lymphoma, early identification and appropriate frontline therapy remains critical, and therapies may vary for those 65 years and older compared with patients under the age of 65, with several additional factors also having a role in approaching treatment options for a new patient in the clinic.

Experts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.

A comprehensive look at the role of bispecific antibodies, including glofitamab, in the treatment of mantle cell lymphoma.

Bijal D. Shah, MD, and Matthew J. Matasar, MD, discuss how they approach treating patients with MCL who rapidly progress on BTK inhibitors.

Bispecific CAR T-cell therapy targeting both CD20 and CD19 cells induced a 90-day complete response rate of 92% in patients with relapsed/refractory mantle cell lymphoma.

Nirav N. Shah, MD, discusses findings from a phase 1/2 study of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens in patients with relapsed or refractory mantle cell lymphoma.

Martin Dreyling, MD, discusses the key safety data from the phase 3 TRIANGLE trial in younger patients with mantle cell lymphoma.

Treatment with brexucabtagene autoleucel in the standard-of-care relapsed/refractory mantle cell lymphoma setting provided an efficacy and safety profile consistent with data reported in the phase 2 ZUMA-2 trial.

A panel of experts in hematologic malignancies analyze clinical studies and real-world data of brexucabtagene autoleucel in mantle cell lymphoma.

Alexey V. Danilov, MD, PhD, presents a second patient profile of a 60-year-old patient with MCL, and the panel discusses using CAR T-cell therapy to treat MCL.

Tycel Phillips, MD, MPH, discusses the key implications of investigating glofitamab monotherapy in patients with relapsed/refractory mantle cell lymphoma.

Andre H. Goy, MD, discusses key findings from an assessment of durable responses in the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

A comprehensive discussion on ways to approach treating patients with high-risk mantle cell lymphoma.

A detailed look at how to select the appropriate BTK inhibitor to treat patients with MCL and the potential role of the non-covalent BTK inhibitor pirtobrutinib in MCL.